ABSTRACT & COMMENTARY

Neurodegeneration Biomarkers in Patients with Subjective Cognitive Complaints

Name: Relias Media
Price range: $

June 15, 2022

In individuals with subjective cognitive decline, multiple biomarkers of neurodegeneration were found to add predictive values beyond amyloid and tau biomarkers.

Issue Date: June 15, 2022

Table of Contents

Financial Disclosure: Dr. Stephen Brunton, physician editor, reports he is on the speakers bureau for AstraZeneca, Bayer, Boehringer Ingelheim, Eli Lilly, and Novo Nordisk; and is a retained consultant for Abbott Diabetes Care, AstraZeneca, Bayer, GSK, and Novo Nordisk. The relevant financial relationships listed have been mitigated. None of the remaining planners or authors for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Subscription Publication Books & Study Guides Group & Site Licenses State CME/CE Requirements